Kotoe Katayama

Kotoe Katayama

Auto-generated profile, based on publicly available information

Kotoe Katayama

Laboratory of Sequence Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
ETEisuke Tomiyama
Eisuke Tomiyama
KFKazutoshi Fujita
Kazutoshi Fujita
KNKosuke Nakano
Kosuke Nakano
KKKen Kuwahara
Ken Kuwahara
TMTakafumi Minami
Takafumi Minami
NNNorio Nonomura
Norio Nonomura
Trophoblast cell surface antigen 2 (Trop-2, encoded by TACSTD2) is the target protein of sacituzumab govitecan, a novel antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma. However, the expression status of Trop-2 in upper tract urothelial carcinoma (UTUC) remains unclear. We performed immunohistochemical analysis of 99 UTUC samples to evaluate the expression status of Trop-2 in patients with UTUC and analyze its association with clinical outcomes. Trop-2 was positive in 94 of the 99 UTUC samples, and high Trop-2 expression was associated with favorable progression-free survival (PFS) and cancer-specific survival (p = 0.0011, 0.0046). Multivariate analysis identified high Trop-2 expression as an independent predictor of favorable PFS (all cases, p = 0.045; high-risk group (pT3≤ or presence of lymphovascular invasion or lymph node metastasis), p = 0.014). Gene expression analysis using RNA sequencing data from 72 UTUC samples demonstrated the association between high TACSTD2 expression and favorable PFS (all cases, p = 0.069; high-risk group, p = 0.029). In conclusion, we demonstrated that Trop-2 is widely expressed in UTUC. Although high Trop-2 expression was a favorable prognostic factor in UTUC, its widespread expression suggests that sacituzumab govitecan may be effective for a wide range of UTUC.

1 March 2020 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
AMAyako Maeda-Minami
Ayako Maeda-Minami
TYTetsuhiro Yoshino
Tetsuhiro Yoshino
KKKotoe Katayama
Kotoe Katayama
YHYuko Horiba
Yuko Horiba
HHHiroaki Hikiami
Hiroaki Hikiami
KWKenji Watanabe
Kenji Watanabe

1 August 2019 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
AMAyako Maeda-Minami
Ayako Maeda-Minami
TYTetsuhiro Yoshino
Tetsuhiro Yoshino
KKKotoe Katayama
Kotoe Katayama
YHYuko Horiba
Yuko Horiba
HHHiroaki Hikiami
Hiroaki Hikiami
KWKenji Watanabe
Kenji Watanabe